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components of the signature in a man-
ner different from what would have
been the case were thymically derived
Treg cells employed. Nevertheless,
and as pointed out by the authors, the
overlap between the genetic signatures
of induced and thymically derived Treg
cells suggests that a TGF-b-related
pathway is already functional in devel-
oping Treg cells in the thymus as well
asbeing operative in the periphery.Not-
withstanding these limitations, the find-
ings of Hill et al. (2007) still present us
with the clearest picture yet of how dis-
parate elements of the Treg cell signa-
ture integrate into one functional tran-
scriptosome. The reappraisal of the
role of Foxp3 from that of a Treg cell lin-
eage commitment factor to one more
involved in the Treg cell-differentiated
functions and phenotype stability paves
the way toward identifying additional
factors influencing Treg cell develop-
ment and differentiated function. A
number of these, such as members of
the nuclear factor of activated T cells
(NFAT) and the acute myeloid leukemia
1-runt-related (Aml1/Runx) transcrip-
tion factor families, have already been
described and others are surely to
follow (Hu et al., 2007).
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Toll-like receptor 7 (TLR7) detects viral RNA, but can be activated inappropriately by self-RNA,
leading to autoimmunity. Deane et al. (2007) show that Tlr7 gene dosage is directly related to the
risk of lupus in a mouse model.The innate immune system not only
rapidly detects pathogens, but can
also distinguish (to some degree)
whether the pathogen is extracellular
or intracellular. The family of Toll-like
receptors (TLRs, ten of which are ex-
pressed in humans) is the best under-
stood of the innate immune receptors
that detect infections. Extracellular
pathogens appear to be detected by
cell-surface TLRs that recognize path-
ogen-expressed molecules such as
diacyl and triacyl lipopeptides and
lipopolysaccharides, in response to
which proinflammatory cytokines such
as TNF-a and IL-12 are secreted. In
contrast, the TLRs that detect intracel-
lular pathogens are expressed intracel-
lularly (in the endosomes and endoplas-
mic reticulum) and detect nucleic acids.The innate immune response to vi-
ruses and other intracellular patho-
gens depends critically on plasmacy-
toid dendritic cells (pDC), which are
highly specialized for producing large
amounts of type I interferon (IFN), re-
quired to control viral replication and
promote the development of a T helper
1 (Th1) response. Perhaps to avoid
their unnecessary activation by extra-
cellular bacteria, pDC do not express
any of the cell-surface TLRs—they
exclusively express the intracellular
TLR7, specific for RNA, and TLR9,
specific for unmethylated DNA. Thus,
pDC secretion of large amounts of
type I IFN can be triggered by either
DNA or RNA viruses.
Unfortunately for the host, endoge-
nous RNA and DNA are able to acti-Immunity 27,vate TLR7 and TLR9 if the RNA enters
the endosomal compartment of the
pDC (or B cells, which also express
both of these TLRs). A rich potential
source of self-RNA and -DNA is the re-
mains of host cells that have died via
necrosis or apoptosis. Normally such
apoptotic debris appears to be cleared
rapidly by macrophages, which in hu-
mans do not express TLR7 or TLR9.
But if there is a delay in apoptotic
clearance, or if there are autoanti-
bodies reactive with the antigens ex-
posed on the apoptotic cells, then
these complexes can be misdirected
into pDC and B cells, where they can
activate TLR7 and/or TLR9 (Figure 1).
The result of this autoactivation is to
induce pDC secretion of type I IFN,
and if the B cell is activated throughNovember 2007 ª2007 Elsevier Inc. 695
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PreviewsFigure 1. TLR7 Activation by Self-RNA Initiates the Type I IFN Cascades, Leading to
Systemic Autoimmunity
Apoptotic blebs, which are enriched in RNA and DNA and their associated proteins, are usually
thought to be cleared by macrophages and are not normally endocytosed in large numbers by
pDC. However, in settings where there is reduced clearance of apoptotic debris, or if the pDC ex-
press increased amounts of TLR7, then the amount of endocytosed RNA may suffice to trigger
TLR7, inducing secretion of type I IFN. Further, in the presence of autoantibodies of appropriate
specificity, the blebs form immune complexes that are readily taken up by pDC, providing a strong
stimulatory signal. Type I IFN promote autoimmunity in multiple ways, including inducing B cells to
express increased TLR7, which may provide a positive-feedback loop exacerbating autoimmunity
(Bekeredjian-Ding et al., 2005). As a result of the synergy between the B cell receptor and TLRs, B
cells specific for RNA- or DNA-associated antigens can get both stimulatory signals and be pref-
erentially stimulated to differentiate into plasma cells. Deane et al. (2007) have now provided
evidence that even relatively modest increases in the expression of TLR7 can result in dramatic
lymphocyte activation and autoimmunity.the B cell receptor, it may undergo dif-
ferentiation into a plasma cell.
In lupus patients, both mechanisms
likely contribute to pDC secretion of
type I IFN: First, there are elevated
numbers of apoptotic cells, and sec-
ond, lupus sera contain autoanti-
bodies against RNA- and DNA-asso-
ciated antigens that are enriched in
apoptotic blebs, such as small nuclear
ribonucleoprotein (snRNP) and chro-
matin (Marshak-Rothstein, 2006; Krieg
and Vollmer, 2007). The resultant
RNA-containing immune complexes
activate pDC through TLR7, and DNA-
containing immune complexes acti-
vate pDC through TLR9 to secrete
IFN-a. Through this mechanism, sys-
temic lupus erythematosus (SLE) pa-
tients have increased serum concen-
trations of IFN-a, which correlate with
disease activity and likely contribute
to disease pathogenesis.
Several mouse models for SLE have
provided insights into the possible
pathogenesis of human SLE. One of
the mouse models that rather closely
mimics disease development in hu-696 Immunity 27, November 2007 ª2007mans is the recombinant inbred line,
BXSB. An unusual feature of SLE in
BXSB mice is the male predominance
of the disease, in contrast to the fe-
male predominance of SLE develop-
ment seen in other mouse models
and humans. Genetic studies revealed
that the Y chromosome of the BXSB
mice bears a locus termed Y chromo-
some-linked autoimmune accelerator
(Yaa), which was derived from the phe-
notypically normal parent strain, SB/
Le. Yaa does not induce autoimmune
disease on all genetic backgrounds,
but rather acts as a disease accel-
erator, promoting SLE in genetically
susceptible mouse strains. Recent ge-
netic studies have revealed that Yaa is
a duplication and translocation of sev-
eral megabases of DNA from the X
chromosome onto the Y chromosome
(Pisitkun et al., 2006; Subramanian
et al., 2006). The duplicated region
contains at least 17 genes, one of
which is Tlr7, which results in a
doubling of the amount of TLR7 pro-
tein and mRNA expression and in
increased responsiveness to TLR7Elsevier Inc.ligands (Pisitkun et al., 2006; Subra-
manian et al., 2006). The fact that Yaa
only induces systemic autoimmunity
in certain susceptible mouse strains
points to a requirement for other back-
ground genes, which for example
could be involved in the clearance of
apoptotic debris or in the production
of autoantibodies to RNA or RNA-
associated antigens, leading to the
autostimulation of TLR7.
Although provocative, the associa-
tion of the Tlr7 duplication with the
autoimmune predisposition of the Yaa
locus did not establish causation. In
this issue of Immunity, Deane et al.
(2007) have now addressed this issue
in a series of elegant experiments
that firmly establish the role of Tlr7
gene dosage in defining the autoim-
mune phenotype induced by Yaa.
First, they reduced the copy number
of Tlr7 in Yaa mice back to normal
by crossing them to TLR7-deficient
mice, so that there could be no X chro-
mosome-derived TLR7 expression.
These mice with a single Tlr7 gene
had a 50% reduction in the spleen
cell proliferation to a TLR7 ligand (to
normal levels) and an even greater
improvement in autoantibody produc-
tion and survival. These experiments
established that the additional copy
of Tlr7 in the Yaa mice is required for
the development of autoimmunity,
and that no other gene(s) in the trans-
location is sufficient. Second, Deane
et al. (2007) addressed the conse-
quences of various degrees of TLR7
overexpression, by using six lines of
transgenic mice bearing from 4 to 32
copies of the gene. Compared to
wild-type mice, TLR7 expression
(measured as mRNA) was increased
in these transgenic lines by 4- to 16-
fold in follicular B cells and by an
even greater margin in DCs. Deane
et al. (2007) noted a direct correlation
between the intensity of TLR7 overex-
pression in the transgenic lines and
both the production of autoantibodies
against RNA and RNA-associated an-
tigens and glomerulonephritis with ac-
celerated mortality. Although Deane
et al. (2007) had expected to have
to cross the Tlr7 transgenes onto a
more autoimmune-prone genetic
background, autoimmunity and mor-
tality were seen even in the founder
Immunity
Previewslines. These studies show for the first
time that even a fairly modest 4–8-
fold overexpression of TLR7 produces
a remarkable spontaneous activation
of DC, T, and B cells already in 2–3-
month-old mice.
The etiology of SLE is multifactorial
and is driven by both genetic and en-
vironmental factors. Several genetic
loci have been associated with an in-
creased risk for SLE, but the relative
risk attributable to each of the genetic
loci identified to date is modest, with
the sole exception of the X chro-
mosome—SLE is approximately nine
times more common individuals with
two X chromosomes (women) com-
pared to men. In fact, although lupus
has one of the most pronounced
sex disparities, nearly all autoimmune
diseases are much more common in
women than in men. Why should
this be? Much early interest in this
question focused on the possible role
of the estrogens and androgens,
which have indisputable immune ac-
tivities, but it is well established that
sex-linked nonhormonal factors are
also important. Could differences in X
chromosome Tlr7 gene dose or ex-
pression contribute to human lupus?
In a study of 190 male and female lu-
pus patients and controls, there was
no lupus-related difference in copy
number of the Tlr7 gene (Kelley et al.,
2007). This suggests that human lupus
is not commonly due to a Yaa-like mu-
tation. Furthermore, Tlr7 seems to be
subjected to the normal X inactivation
mechanisms because there is no dif-
ference in the expression of TLR7
mRNA between either B cells or pDCfrom men and women (Berghofer
et al., 2006). In contrast to the appar-
ently normal regulation of the X chro-
mosome Tlr7, the translocated seg-
ment in Yaa mice seems not to be
subject to the normal X inactivation,
resulting in an approximate 2-fold in-
crease in the amount of TLR7 mRNA
in spleen B cells of Yaa male mice
compared to littermate control fe-
males or to wild-type males (Subrama-
nian et al., 2006). Despite the similarity
in TLR7 expression between men and
women, the small-molecule TLR7 li-
gand R-848 induces peripheral blood
mononuclear cells (PBMCs) from
women to secrete markedly more
IFN-a than do PBMCs from males
(Berghofer et al., 2006). The mecha-
nism for this greater sensitivity to
TLR7 in women is unclear, and the
possibility that TLR7 expression or
function is somehow regulated dif-
ferently in women and men will doubt-
less be the subject of further study. In
addition, there is a need for investi-
gations comparing the sensitivity of
pDC or B cells from men and women
to RNA (the physiologic ligand for
TLR7) and RNA-containing immune
complexes.
Abnormal increases in TLR7 expres-
sion are not required for the devel-
opment of autoimmune disease: Phy-
siologic amounts of TLR7 drive SLE
development in mice bearing the lpr
mutation (Christensen et al., 2006)
and mice transgenic for a polyreactive
BCR that binds RNA, DNA, and chro-
matin (Berland et al., 2006). The cur-
rent studies will intensify interest in
the role of TLR7 in autoimmune etiopa-Immunity 27,thogenesis, and they point to TLR7
and the associated signaling pathways
as potential therapeutic targets.
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